Melatonin is not regulated by the FDA the way medications are. In the United States, melatonin is classified as a dietary supplement, which means it does not go through the rigorous pre-market safety and efficacy testing that prescription and over-the-counter drugs require. The FDA has limited oversight over melatonin products, and that gap has real consequences for what ends up on store shelves.
How Melatonin Is Classified in the US
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), melatonin falls into the same regulatory category as vitamins, minerals, and herbal products. This means manufacturers don’t need to prove that their melatonin product is safe or effective before selling it. They only need to notify the FDA 75 days in advance if they’re introducing a “new dietary ingredient,” along with evidence that it can reasonably be expected to be safe. For melatonin, which has been sold as a supplement for decades, even that step doesn’t apply.
Manufacturers can make general claims about what melatonin does for the body, like “supports healthy sleep,” but they’re required to include a disclaimer on the label: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” The label must also list each ingredient and its quantity. Beyond those basic requirements, the FDA largely stays out of the picture until a problem is reported.
What the FDA Actually Oversees
The FDA’s role with melatonin is reactive, not preventive. Rather than testing products before they hit the market, the agency monitors safety complaints after they’re already being sold. Consumers and healthcare providers can report adverse events through MedWatch, the FDA’s safety reporting program. If enough problems surface with a specific product, the FDA can issue warnings, request recalls, or take enforcement action. But the burden of proof falls on the FDA to show a product is unsafe, not on the manufacturer to prove it’s safe. That’s the opposite of how prescription drugs work.
Label Accuracy Is a Real Problem
The lack of pre-market testing shows up clearly in product quality. A study published in JAMA analyzed 25 melatonin gummy products sold in the US and found that 88% were inaccurately labeled. Only 3 out of 25 products contained a melatonin quantity within 10% of what the label claimed. The actual melatonin content ranged from 74% to 347% of the labeled amount. That means some products contained more than three times the dose you thought you were taking, while others delivered significantly less.
This kind of inconsistency is a direct result of the regulatory framework. Because melatonin isn’t held to pharmaceutical manufacturing standards, there’s no requirement for the FDA to verify that the dose on the label matches what’s in the product.
Why This Matters for Children
The regulatory gap becomes especially concerning when it comes to kids. Between 2012 and 2021, pediatric melatonin ingestions reported to US poison control centers increased by 530%, from 8,337 cases to 52,563. By 2021, melatonin accounted for 4.9% of all pediatric ingestions reported to poison control, up from just 0.6% in 2012. The largest single-year jump, nearly 38%, happened between 2019 and 2020.
Most of these cases involved unintentional ingestions by children five and younger, likely drawn to flavored gummies that look and taste like candy. Hospitalizations increased alongside the overall numbers. Five children required mechanical ventilation during the study period, and two died. The CDC has called for public health initiatives focused on safe storage and raising awareness about the risks, and the FDA encourages reporting any melatonin-related adverse events through MedWatch. But no new packaging or child-safety requirements have been imposed.
How Other Countries Handle Melatonin
The US approach is unusual. In Australia, the United Kingdom, and Switzerland, melatonin is classified as a prescription-only medicine. It cannot legally be sold as a dietary supplement in those countries. That means a doctor must evaluate whether melatonin is appropriate for you, and the product itself is manufactured to pharmaceutical standards with verified dosing.
This contrast highlights a key point: the science of melatonin isn’t what differs between countries. The regulatory philosophy does. Many nations treat melatonin as a hormone that warrants medical oversight. The US treats it more like a vitamin.
Third-Party Certifications Fill the Gap
Because the FDA doesn’t verify supplement quality before sale, third-party certification programs have stepped in. NSF International developed the first independent testing standard specifically for dietary supplements. Their certification program has three components: verifying that the label accurately reflects the contents, reviewing the formulation for safety through toxicology analysis, and checking for undeclared ingredients or unacceptable contaminant levels.
Unlike programs that test a single sample and move on, NSF conducts testing in its own accredited labs, performs annual audits, and periodically retests certified products. Products that pass carry the NSF certification mark. USP (United States Pharmacopeia) runs a similar verification program. If you’re choosing a melatonin product, looking for one of these seals is the closest thing to a quality guarantee you’ll find in the supplement aisle. Neither program tests whether melatonin actually works for your sleep issues, but they do confirm that the bottle contains what it says it contains, at the dose it claims, without harmful contaminants.
Prescription Alternatives That Are FDA-Approved
There are FDA-approved prescription medications that work on the same brain receptors as melatonin. These drugs went through the full approval process, meaning they were tested in clinical trials for both safety and effectiveness before reaching patients. They’re manufactured under strict pharmaceutical quality controls, so the dose is reliable every time. If you’re using melatonin for a persistent sleep problem and want the assurance of FDA oversight, a prescription alternative is worth discussing with your doctor.
The bottom line is that melatonin occupies a regulatory gray zone. The FDA has some authority over it, but far less than most people assume when they pick up a bottle at the pharmacy. The product doesn’t require pre-market approval, the dose on the label may not match what’s inside, and no child-resistant packaging is mandated. Understanding these limitations helps you make more informed choices about what you’re actually buying.